DNMT3A and Alzheimer disease: In this study, we summarize population-based cohort studies reporting a 36 to 54% reduction in the odds of clinical AD among CHIP carriers, alongside emerging data indicating that <i>DNMT3A</i> and <i>TET2</i> mutations may exert divergent effects on neurodegeneration.